|1.||Palumbo, Antonio: 2 articles (06/2014 - 07/2011)|
|2.||Waddell, J Aubrey: 1 article (01/2015)|
|3.||Solimando, Dominic A: 1 article (01/2015)|
|4.||Bryant, Samantha: 1 article (01/2015)|
|5.||Grosicki, Sebastian: 1 article (06/2014)|
|6.||Qin, Xiang: 1 article (06/2014)|
|7.||Prasad, Sripada V S S: 1 article (06/2014)|
|8.||Tee Goh, Yeow: 1 article (06/2014)|
|9.||Bladé, Joan: 1 article (06/2014)|
|10.||Spencer, Andrew: 1 article (06/2014)|
|1.||Plasma Cell Leukemia
|2.||Neoplasm Metastasis (Metastasis)
12/01/2004 - "This study was designed to compare therapeutic effects,toxicities,and survival time of 2 different sequential treatments of VmP regimen and WBRT for SCLC patients with brain metastases. "
12/01/2004 - "[Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases]."
01/01/2015 - "Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma."
06/01/2014 - "Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study."
06/26/2014 - "Because interleukin-6 (IL-6) is considered important in the proliferation of early multiple myeloma (MM), we hypothesized that the addition of the anti-IL-6 monoclonal antibody siltuximab to the bortezomib-melphalan-prednisone (VMP) regimen would improve outcomes in transplant-ineligible patients with newly diagnosed MM. One hundred and six patients were randomized to receive 9 cycles of VMP or VMP plus siltuximab (11 mg/kg every 3 weeks) followed by siltuximab maintenance. "
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|4.||Interleukin-6 (Interleukin 6)
|5.||Immunoglobulin E (IgE)
|6.||monoclonal antibody CNTO 328